SG11201911776PA - 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases - Google Patents

15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases

Info

Publication number
SG11201911776PA
SG11201911776PA SG11201911776PA SG11201911776PA SG11201911776PA SG 11201911776P A SG11201911776P A SG 11201911776PA SG 11201911776P A SG11201911776P A SG 11201911776PA SG 11201911776P A SG11201911776P A SG 11201911776PA SG 11201911776P A SG11201911776P A SG 11201911776PA
Authority
SG
Singapore
Prior art keywords
beta
propanamido
trien
oximes
inhibition
Prior art date
Application number
SG11201911776PA
Other languages
English (en)
Inventor
Leena Hirvelä
Marjo Hakola
Tero Linnanen
Pasi Koskimies
Camilla Stjernschantz
Original Assignee
Forendo Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forendo Pharma Ltd filed Critical Forendo Pharma Ltd
Publication of SG11201911776PA publication Critical patent/SG11201911776PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016Oximes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0044Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an estrane or gonane skeleton, including 18-substituted derivatives and derivatives where position 17-beta is substituted by a carbon atom not directly bonded to another carbon atom and not being part of an amide group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201911776PA 2017-06-08 2018-06-07 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases SG11201911776PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20175530 2017-06-08
PCT/FI2018/050427 WO2018224736A2 (en) 2017-06-08 2018-06-07 Therapeutically active steroidal derivatives

Publications (1)

Publication Number Publication Date
SG11201911776PA true SG11201911776PA (en) 2020-01-30

Family

ID=62716091

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201911776PA SG11201911776PA (en) 2017-06-08 2018-06-07 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases

Country Status (19)

Country Link
US (3) US10717761B2 (zh)
EP (1) EP3634975B1 (zh)
JP (3) JP7064515B2 (zh)
KR (1) KR102420512B1 (zh)
CN (2) CN115716860A (zh)
AU (1) AU2018279205B2 (zh)
CA (1) CA3066196C (zh)
CL (1) CL2019003562A1 (zh)
DK (1) DK3634975T3 (zh)
EA (1) EA201992826A1 (zh)
FI (1) FI3634975T3 (zh)
IL (2) IL294140B1 (zh)
MX (2) MX2022000747A (zh)
NZ (1) NZ760155A (zh)
PT (1) PT3634975T (zh)
SG (1) SG11201911776PA (zh)
UA (1) UA126342C2 (zh)
WO (1) WO2018224736A2 (zh)
ZA (1) ZA201908404B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220041647A1 (en) * 2018-12-05 2022-02-10 Forendo Pharma Ltd Estra-1,3,5(10)-triene compounds condensed in position 16(17) with a pyrazole ring as inhibitors of 17-hsd1
CN114644673B (zh) * 2020-12-19 2023-12-26 上海喀露蓝科技有限公司 一种雌二醇衍生物、其制备方法及其在医药上的用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2323089A1 (en) 1998-03-11 1999-09-16 Endorecherche, Inc. Inhibitors of type 5 and type 3 17.beta.-hydroxysteroid dehydrogenase and methods for their use
GB9929302D0 (en) 1999-12-11 2000-02-02 Univ Cardiff Benzyl tetralins compositions and uses thereof
AR036492A1 (es) 2001-09-06 2004-09-15 Schering Corp Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes
MXPA04003611A (es) 2001-10-17 2004-07-30 Schering Corp Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
ES2345146T3 (es) 2002-11-18 2010-09-16 Schering Corporation Inhibidores de 17beta-hidroxiesteroides deshidrogenasa de tipo 3 para el tratamiento de enfermedades dependientes de androgenos.
JP4585320B2 (ja) 2002-12-17 2010-11-24 シェーリング コーポレイション 男性ホルモン依存性疾患の処置のための17β−ヒドロキシステロイドデヒドロゲナーゼ3型インヒビター
WO2004085345A2 (en) 2003-03-21 2004-10-07 Yale University 15α-SUBSTITUTED ESTRADIOL CARBOXYLIC ACID ESTERS AS LOCALLY ACTIVE ESTROGENS
GB0306718D0 (en) 2003-03-24 2003-04-30 Sterix Ltd Compound
US20040224935A1 (en) 2003-04-07 2004-11-11 Endorecherche, Inc. Topical antiandrogenic steroids
US7754709B2 (en) 2003-06-10 2010-07-13 Solvay Pharmaceuticals Bv Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds
US7465739B2 (en) 2003-06-10 2008-12-16 Solvay Pharmaceuticals B.V. Compounds and their use in therapy
US8088758B2 (en) * 2003-11-12 2012-01-03 Abbott Products Gmbh 17β-hydroxysteroid dehydrogenase type I inhibitors
TWI331154B (en) * 2003-11-12 2010-10-01 Solvay Pharm Gmbh Novel 17-hydroxysteroid dehydrogenase type i inhibitors
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
DE102004032673A1 (de) 2004-07-02 2006-01-26 Schering Ag Neue 2-substituierte D-Homo-estra-1,3,5(10)-triene als Inhibitoren der 17ß-Hydroxysteroiddehydrogenase Typ 1
DE102004032674A1 (de) 2004-07-02 2006-01-26 Schering Ag Neue 2-substituierte Estra-1,3,5(10)-trien-17-one als Inhibitoren der 17β-Hydroxysteroiddehydrogenase Typ 1
US7575828B2 (en) 2004-07-23 2009-08-18 Kim Manufacturing Co. Modular rack assemblies for sealed lead acid batteries
UA89964C2 (ru) 2004-09-08 2010-03-25 Н.В. Органон 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ
RU2412196C2 (ru) 2005-05-26 2011-02-20 Зольвай Фармасьютиклз Гмбх ИНГИБИТОРЫ 17β-ГСД1 И СТС
US8030298B2 (en) * 2005-05-26 2011-10-04 Abbott Products Gmbh 17β-HSD1 and STS inhibitors
RU2469042C2 (ru) 2006-09-19 2012-12-10 Зольвай Фармасьютиклз Гмбх Терапевтически активные триазолы и их использование
EP2099814A1 (en) 2006-11-30 2009-09-16 Solvay Pharmaceuticals GmbH Substituted estratrien derivatives as 17beta hsd inhibitors
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
EP2376408A4 (en) 2008-11-20 2012-06-20 Harvard College FLUORATION OF ORGANIC COMPOUNDS
CA2830984C (en) 2011-03-25 2020-02-11 Universite Laval Inhibitors of 17.beta.-hsd1, 17.beta.-hsd3 and 17.beta.-hsd10.
CN105518015B (zh) * 2013-06-25 2017-09-15 佛恩多制药有限公司 治疗活性的作为17β‑羟基类固醇脱氢酶抑制剂的17‑氮取代雌三烯噻唑衍生物
CN105518016B (zh) * 2013-06-25 2020-10-23 佛恩多制药有限公司 治疗活性的作为1型17β-羟基类固醇脱氢酶抑制剂的雌三烯噻唑衍生物
CN105518017B (zh) * 2013-06-25 2020-07-14 佛恩多制药有限公司 治疗活性的作为1型17β-羟基类固醇脱氢酶抑制剂的雌三烯噻唑衍生物
US10413557B2 (en) 2014-12-23 2019-09-17 Forendo Pharma Ltd. Prodrugs of 17.BETA.-HSD1-inhibitors
EP3237430B1 (en) 2014-12-23 2019-03-20 Forendo Pharma Ltd PRODRUGS OF 17ß -HSD1 -INHIBITORS

Also Published As

Publication number Publication date
IL271218A (en) 2020-01-30
EA201992826A1 (ru) 2020-05-14
IL294140A (en) 2022-08-01
KR20200023362A (ko) 2020-03-04
JP2020522539A (ja) 2020-07-30
MX2022000747A (es) 2023-01-24
WO2018224736A2 (en) 2018-12-13
JP2024028916A (ja) 2024-03-05
AU2018279205B2 (en) 2021-04-15
US10717761B2 (en) 2020-07-21
WO2018224736A3 (en) 2019-01-17
CN110945007A (zh) 2020-03-31
JP7401576B2 (ja) 2023-12-19
MX2019014677A (es) 2022-04-01
US20220127303A1 (en) 2022-04-28
CL2019003562A1 (es) 2020-06-12
KR102420512B1 (ko) 2022-07-13
EP3634975B1 (en) 2024-02-28
CN110945007B (zh) 2022-11-18
JP2022065030A (ja) 2022-04-26
IL294140B1 (en) 2024-05-01
JP7064515B2 (ja) 2022-05-10
CA3066196A1 (en) 2018-12-13
BR112019025782A2 (pt) 2020-06-23
ZA201908404B (en) 2023-11-29
AU2018279205A1 (en) 2020-01-16
DK3634975T3 (da) 2024-05-27
EP3634975A2 (en) 2020-04-15
CA3066196C (en) 2023-08-29
UA126342C2 (uk) 2022-09-21
FI3634975T3 (fi) 2024-05-03
CN115716860A (zh) 2023-02-28
NZ760155A (en) 2022-09-30
PT3634975T (pt) 2024-05-20
US20180354984A1 (en) 2018-12-13
US20200317718A1 (en) 2020-10-08
US11254703B2 (en) 2022-02-22

Similar Documents

Publication Publication Date Title
Liu et al. Liu
SG11202104495YA (en) Pyridazine derivatives as smarca2/4 degraders
MX2020012602A (es) Composiciones bacterianas dise?adas y usos de las mismas.
MY190855A (en) Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
EP3572050A4 (en) EXCREMENT TREATMENT AGENT FOR USE IN COLOSTOMIES
PH12019550096A1 (en) Beta-casein a2 and prevention of inflammation of the bowel
MX2019009842A (es) Composicion solida que comprende sofosbuvir amorfo.
DK3657954T3 (en) Non-hydrogenated fat composition, use and process
EP3332012A4 (en) GLP-1 AND USE THEREOF IN COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES
EP3626709A4 (en) INDAZOLE COMPOUND FOR USE IN INHIBITING KINASE ACTIVITY, COMPOSITION AND APPLICATION THEREOF
IL284183A (en) 3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and their preparations
ZA201905094B (en) Methods and microorganisms for making 2,3-butanediol and derivatives thereof from c1 carbons
SG11201908281VA (en) Phenalene-1-one-containing photosensitizer composition, phenalene-1-one compound and the use thereof
EP3337482A4 (en) TRANSDERMAL FORMULATIONS FOR THE DISTRIBUTION OF BERBERIN COMPOUNDS AND THEIR USE IN THE TREATMENT OF BERBER INDEPENDENT ILLNESSES AND DISORDERS
MX2016008851A (es) Compuesto esteroideo para su uso en el tratamiento de encefalopatia hepatica.
EP3595689A4 (en) METHODS AND COMPOSITIONS FOR TREATING OBESITY, INFLAMMATION OR METABOLIC DISORDERS WITH BACTERIOPHAGES
SG11202105012VA (en) Aromatic ring-linked dioxino-quinazoline or dioxino-quinoline compounds, compositions and use thereof
IL271218A (en) 15 beta-[3-propanoamido] ester-1, 3, 5(10)-trien-17-one substances and their 17-oximes used in the inhibition of 17 beta-hydroxysteroid dehydrogenases
MX2021005038A (es) Dispersiones solidas y composiciones farmaceuticas que comprenden un indano sustituido y metodos para la preparacion y uso de las mismas.
EP3210614A4 (en) Composition containing thymosin beta 4, and pharmaceutical formulation comprising same
GB2579240B (en) New processes, compositions and medical uses
EP3607949A4 (en) COMPOSITION FOR THE PREVENTION AND TREATMENT OF MUSCLE DISEASES
EP3710003A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR SELECTIVELY INHIBITING BETA-GLUCURONIDASES AND ATTENUATING SIDE EFFECTS ASSOCIATED WITH DIARRHEA CAUSED BY DRUG TREATMENT
EP3430056A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF ALPHA-8-BETA-1-INTEGRIN ASSOCIATED DISEASES
IL283588A (en) Compounds 1, 3, 5(10)-triane condensed at position 16(17) with a pyrazole ring as 17-hsd1 inhibitors